Galectin Therapeutics released its fourth‑quarter 2025 earnings on March 31, 2026, reporting a net loss. The exact earnings‑per‑share figure was not disclosed in the available sources, but the consensus estimate for the quarter was a loss of $0.10 per share. Revenue for the period remained at $0.00, consistent with the company’s pre‑revenue status.
Operating expenses were largely unchanged from the prior quarter, indicating disciplined cost management. The company’s cash position remains limited, with a projected runway through April 2027 supported by existing cash and a $10 million credit line.
Management emphasized progress on the belapectin program. CEO Joel Lewis said, “We are at an important juncture for the belapectin development program. During 2025, we made meaningful progress advancing the belapectin program and continuing our analysis of the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. We are encouraged by the signals observed….” Chief Medical Officer Khurram Jamil added, “Importantly, the concordant biomarker data across independent measures support the mechanistic rationale for Galectin‑3 inhibition and highlight belapectin’s potential to favorably alter disease trajectory in patients with advanced, high‑risk MASH cirrhosis.”
The company remains under regulatory scrutiny, having received written feedback from the FDA on the design of its pivotal belapectin trial, and is currently the subject of a securities law investigation by Pomerantz LLP. These factors underscore the high‑risk nature of the business and the need for additional capital to sustain its clinical program.
With no product revenue and a limited cash runway, the company’s Q4 results provide a modest update on its financial position but do not materially alter its long‑term outlook. Investors will continue to monitor the company’s progress on belapectin and its ability to secure additional funding.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.